Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
ID: 348732Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348732

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-194.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced the Substance Use/Substance Use Disorder Dissertation Research Award (R36), aimed at supporting doctoral candidates in completing their dissertation research projects related to substance use and substance use disorders. This grant, which provides funding of up to $50,000 annually for a maximum of two years, is specifically designed for research that does not involve independent clinical trials, although candidates may engage in ongoing trials under mentorship. The program emphasizes inclusivity, encouraging applications from individuals from diverse and underrepresented backgrounds, and requires applicants to be U.S. citizens or lawful permanent residents who have completed all institutional requirements for their dissertation by the time of the award. Interested applicants should note that the application process is open until September 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-194.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-194-Full-Announcement.html
    PAR-23-194.html
    The National Institutes of Health (NIH), via the National Institute on Drug Abuse (NIDA), has announced the Substance Use/Substance Use Disorder Dissertation Research Award (R36) as part of its funding initiatives. This program aims to support doctoral candidates in completing their dissertation research aligned with NIDA's strategic plan, particularly focusing on substance use and substance use disorder research. The funding will be capped at $50,000 annually for up to two years and is specifically designed for research that does not involve independent clinical trials, although candidates may participate under mentorship in ongoing trials. The application process emphasizes inclusivity, encouraging submissions from individuals from diverse and underrepresented backgrounds. Key eligibility requirements include being a U.S. citizen or a lawful permanent resident, and the completion of all institutional requirements for the dissertation stage is necessary by the time of the award. Application dates are set for October 16, 2023, with ongoing submission cycles until 2026, and potential applicants are urged to follow specific guidelines to ensure compliance. This funding opportunity reflects the government's commitment to nurturing new talent in substance use research, aiming to address critical public health issues through academic inquiry and innovation.
    Similar Opportunities
    NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Mentored Clinical Scientist Development Program Award (K12), aimed at advancing research in substance use and substance use disorders (SUD). This funding opportunity supports clinician scientists through intensive mentorship and research experiences over a period of 3-4 years, requiring eligible scholars to hold a doctoral degree and dedicate at least 75% of their effort to research and career development. The program emphasizes the importance of fostering a diverse scientific workforce and requires applicants to include a recruitment plan to enhance diversity, alongside a structured career development and research plan aligned with NIDA’s mission. Interested applicants should note that the application submission window opens on February 6, 2024, with a funding ceiling of $750,000 per year for direct costs. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIDA's funding announcement.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Aging Research Dissertation Awards to Promote Diversity (R36), aimed at supporting graduate students from diverse backgrounds engaged in aging-related health research. This funding opportunity encourages applications from underrepresented groups in the biomedical and behavioral sciences, with the goal of enriching the research workforce and addressing complex health challenges in an aging population. The NIH anticipates awarding approximately 10 grants annually, with a total investment of around $768,420 between FY 2025 and 2027, providing up to $42,500 for individual salaries and up to $28,656 for additional research-related expenses. Interested applicants must submit their proposals by January 16, 2024, with awards expected to commence in July 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), specifically through the National Institute on Aging (NIA), is offering Aging Research Dissertation Awards (R36) aimed at promoting diversity within the scientific research workforce focused on aging and health-related issues. This funding opportunity is designed for senior graduate students from underrepresented backgrounds in biomedical and behavioral sciences, supporting their dissertation research in various aging-related fields. NIH allocates approximately $768,420 annually for up to 10 awards from FY 2025 to 2027, with each award covering up to $42,500 in salary and $28,656 for additional expenses, excluding tuition. Interested applicants should note that the application process begins on January 16, 2025, with a final submission deadline of November 17, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-130.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)," aimed at advancing translational research in the field of substance use. This initiative encourages researchers to engage in a two-phase research process, starting with an R61 planning phase lasting up to two years, followed by an R33 phase for larger studies that may extend up to four years, contingent upon meeting specific milestones. The program emphasizes the importance of community stakeholder engagement and mandates a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals to ensure inclusivity in research development. Interested applicants can find more information and submit their proposals by December 14, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data." This initiative invites applications that propose innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to investigate the etiology and epidemiology of substance use behaviors and related disorders, including HIV prevention and health service utilization. The program aims to leverage public datasets to enhance understanding of substance use trajectories and effective prevention strategies, particularly focusing on underrepresented populations and health disparities. A total funding commitment of $2 million is available for fiscal year 2026, with applications due by January 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, aimed at supporting innovative research that intersects HIV and substance use disorders. This grant opportunity encourages creative scientists to propose high-impact studies that lead to new therapies and preventative strategies for HIV among drug users, emphasizing originality and alignment with NIH’s HIV/AIDS research priorities. The program allows for clinical trial proposals with a funding ceiling of $700,000 per year for up to five years, with applications due by August 15, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.